ArticleEuropean journal of dentistry2026
Circular RNAs in Oral Squamous Cell Carcinoma: A Systematic Review of Emerging Diagnostic and Prognostic Biomarkers.
Article in European journal of dentistry, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Abstract: Oral squamous cell carcinoma (OSCC) remains a major global health burden, with poor survival rates due to late diagnosis and limited prognostic precision. Circular RNAs (circRNAs) are a novel class of non-coding RNAs characterized by their covalently closed loop structure, conferring stability and tissue specificity. Recent evidence suggests circRNAs hold promise as diagnostic and prognostic biomarkers in OSCC. This article aims to systematically evaluate the diagnostic accuracy, prognostic value, and expression profiles of circRNAs in OSCC. We searched PubMed, Scopus, EBSCO, and Google Scholar databases (inception-August 2025) for studies assessing circRNAs in OSCC. Eligible studies reported diagnostic metrics (sensitivity, specificity, and AUC), prognostic outcomes (hazard ratios [HRs]), or differential expression data. Risk of bias was assessed using QUADAS-2 and NOS. Data were synthesized qualitatively. A total of 29 studies were included. Tissue-based circRNAs showed moderate diagnostic performance (AUC: 0.74-0.81), while saliva- and plasma-derived circRNAs demonstrated higher accuracy (AUC up to 0.922). Prognostic studies revealed oncogenic circRNAs were associated with poor overall survival (pooled OS HR ≈ 2.38), whereas tumor-suppressor circRNAs predicted favorable outcomes (pooled OS HR ≈ 0.43). Exosomal circRNAs, particularly circ-0000199, emerged as independent predictors of recurrence and mortality. CircRNAs exhibit strong potential as diagnostic and prognostic biomarkers in OSCC, particularly in liquid biopsy applications. However, heterogeneity, small sample sizes, and lack of multicenter validation limit immediate clinical translation. Larger, standardized studies are warranted to confirm their utility.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.